Health score, price, valuation, risk signals, and key metrics at a glance.
Alexandria Real Estate Equities, Inc., an S&P 500 registered company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus ecosystems in AAA life science and advanced technology innovation cluster locations, including Greater Boston, San Diego, the San Francisco Bay Area, Seattle, Maryland, Research Triangle, and New York City. As of June 30, 2026, Alexandria has a total market capitalization of 21.84 billion dollar and an asset base that includes 36.0 million RSF of operating properties and 2.8 million RSF of Class A/A+ properties undergoing construction. Alexandria has a long-standing and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Megacampus environments that enhance our tenants' ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. Alexandria Real Estate Equities, Inc. was established in 1994 and incorporated in Maryland.
Strongest: Balance Sheet & Red Flags (17/25); weakest: Cash & Earnings Quality (5/25).
Today's multiple positioned against its own trailing range — a visual premium/discount check.
Currently above its 15-quarter median.
Currently below its 20-quarter median.
Currently below its 20-quarter median.
Data-driven signals worth keeping an eye on across the last 8 quarters
Operating margins dropped 27.9% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.
Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.
Revenue declined in 6 of the last 7 quarters — persistent contraction signals a fundamental problem.
The last 4 consecutive quarters had negative FCF — the company is burning cash and may need external funding.
as of June 2026
Revenue, EBITDA, operating income, net income, EPS, and shares
Gross, EBITDA, operating, and net margin trends
P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield
Total assets, cash, debt, book value, and leverage
Operating cash flow, free cash flow, FCF margin, and earnings quality
